2011
MP-16.01 Cellular and Humoral Immune System Activation by Sipuleucel-T: Preliminary Data from the OpenACT Phase 2 Trial
Petrylak D, Corman J, Hall S, Nabhan C, Ferrari A, Armstrong A, Dawson N, Sims R, Stewart F, Sheikh N. MP-16.01 Cellular and Humoral Immune System Activation by Sipuleucel-T: Preliminary Data from the OpenACT Phase 2 Trial. Urology 2011, 78: s147. DOI: 10.1016/j.urology.2011.07.369.Peer-Reviewed Original Research
2005
A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data
Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaula R, Beer T, Eisenberger M. A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data. Journal Of Clinical Oncology 2005, 23: 4565-4565. DOI: 10.1200/jco.2005.23.16_suppl.4565.Peer-Reviewed Original ResearchChemotherapy agents and timing of chemotherapy in prostate cancer management
Donohue K, Petrylak D. Chemotherapy agents and timing of chemotherapy in prostate cancer management. Current Prostate Reports 2005, 3: 58-61. DOI: 10.1007/s11918-005-0017-1.Peer-Reviewed Original ResearchHormone-refractory prostate cancerSurvival benefitProstate cancerMetastatic hormone-refractory prostate cancerProstate-specific antigen levelTiming of chemotherapyPhase 2 trialProstate cancer managementMedian survivalPalliative benefitSurvival improvementAntigen levelsClinical trialsChemotherapy agentsCancer managementSingle agentChemotherapeutic agentsDocetaxelTrialsPhase 3Preliminary dataChemotherapyEstramustinePatientsCancer
2004
Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial
Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaola R, Beer T, Eisenberger M. Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. Journal Of Clinical Oncology 2004, 22: 4649-4649. DOI: 10.1200/jco.2004.22.14_suppl.4649.Peer-Reviewed Original ResearchAdjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial
Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaola R, Beer T, Eisenberger M. Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. Journal Of Clinical Oncology 2004, 22: 4649-4649. DOI: 10.1200/jco.2004.22.90140.4649.Peer-Reviewed Original Research